| Previous Close | 34.17 |
| Open | 34.16 |
| Bid | 34.09 x 4900 |
| Ask | 34.10 x 5900 |
| Day's Range | 33.97 - 34.20 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 6,871,705 |
| Avg. Volume | 21,623,077 |
| Market Cap | 203.35B |
| Beta | 1.06 |
| PE Ratio (TTM) | 28.68 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.75%) |
| Ex-Dividend Date | 2017-05-10 |
| 1y Target Est | N/A |
- Market Realist•17 minutes ago
Pfizer Has Received Commercial Rights for Cresemba in Europe
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
- Investopedia•2 hours ago
Pfizer Stock Looks Pretty Bullish for the Long Term
After spending much of the last two months in a slow decline, shares of Pfizer have broken out of their downtrend.
- Market Realist•2 hours ago
Pfizer’s Xeljanz: Results from the ORAL Strategy
On June 16, 2017, Pfizer announced detailed results from its ORAL (Oral Rheumatoid Arthritis TriaL) Strategy.
